Medicenna Therapeutics Corp (TSE:MDNA) has released an update.
Medicenna Therapeutics Corp has presented promising preclinical results for two novel treatments at the Promise of Interleukin-2 Therapy Conference. Their IL-2 Super-antagonist, MDNA209, shows potential in treating autoimmune diseases by significantly improving survival rates in a GvHD animal model. Meanwhile, their targeted BiSKIT therapy, MDNA113, exhibited enhanced efficacy in tumors overexpressing IL-13Rα2, offering hope for hard-to-treat cancers.
For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.
